ライフサイエンスコーパス: obese patient

1 r fitness and survival in some overweight or obese patients.

2 mpared bariatric surgery with usual care for obese patients.

3 disease and may have a better prognosis than obese patients.

4 of mice fed a high-fat diet (HFD) as well as obese patients.

5 ta-catenin in physically fit, overweight and obese patients.

6 tsurgical elovl6 gene expression in morbidly obese patients.

7 and appears to be well tolerated in severely obese patients.

8 c use of leptin in overweight and moderately obese patients.

9 standing the pathogenesis of lung disease in obese patients.

10 regimens for iGAS may improve prognoses for obese patients.

11 ting neuromuscular-blocking agents doses for obese patients.

12 type are mobilized and infiltrate tumours in obese patients.

13 es of 15 obese patients compared with 16 non-obese patients.

14 ting when caring for critically ill morbidly obese patients.

15 oments were evident when caring for morbidly obese patients.

16 pose tissue (VAT) of metabolically unhealthy obese patients.

17 as weight loss, that may be advantageous in obese patients.

18 ase and anthropometric measures in Class III obese patients.

19 ws screening of NAFLD as well as fibrosis in obese patients.

20 the risk of promoting insulin resistance in obese patients.

21 gher vulnerability to atrial fibrillation of obese patients.

22 n blood microbiota are associated with LF in obese patients.

23 r optimal mechanical ventilation of morbidly obese patients.

24 odynamics and pharmacokinetic variability in obese patients.

25 lating neuromuscular-blocking agent doses in obese patients.

26 Outcome in the long term is best in super obese patients.

27 y best performed using actual body weight in obese patients.

28 ry fitness and incident AF, especially among obese patients.

29 ese compared with nonobese, especially among obese patients.

30 rnia (28.3% vs 14.8% vs 20.3%, P = 0.01) for obese patients.

31 isolated from subcutaneous adipose tissue of obese patients.

32 ment for the treatment of type 2 diabetes in obese patients.

33 s and improves insulin sensitivity (S(I)) in obese patients.

34 in resistance pattern compared with morbidly obese patients.

35 e performed safely and efficiently in mildly obese patients.

36 clear benefit to weight gain for overweight/obese patients.

37 cessive mortality compared with noncirrhotic obese patients.

38 ght and cardiovascular mortality in morbidly obese patients.

39 his population was even undetectable in some obese patients.

40 t outcomes observed in overweight and mildly obese patients.

41 breaks down and shows low SUL values in very obese patients.

42 s found in adipose tissue of type 2 diabetic obese patients.

43 ation was also observed in the arteries from obese patients.

44 tools for screening of NAFLD and fibrosis in obese patients.

45 ens with age in human mature adipocytes from obese patients.

46 s effective and safe as warfarin in morbidly obese patients.

47 op novel therapeutic approaches for treating obese patients.

48 ted with increased CV risk in overweight and obese patients.

49 Suboptimal position was more common in obese patients.

50 st cancer in a rapidly growing population of obese patients.

51 st cancer in a rapidly growing population of obese patients.

52 paigns can improve the prognosis of severely obese patients.

53 eting p110gamma for therapy, particularly in obese patients.

54 ncing of these loci in endometrial tumors of obese patients.

55 e visceral fat of two obese mouse models and obese patients.

56 bin or fibrin(ogen) may limit pathologies in obese patients.

57 for achieving clinical control of asthma in obese patients.

58 tly related to electroanatomic remodeling in obese patients.

59 pe 2 diabetics (8.8% vs 5.5%; P = .046), and obese patients (11.7% vs 4.0%; P < .001).

60 Of these obese patients, 2256 (83%) agreed to participate and 188

61 motility and hormonal responses in morbidly obese patients after sleeve gastrectomy has not been det

62 Better survival for overweight and obese patients after ST-segment-elevation myocardial inf

63 Morbidly obese patients also benefited more from LT (88% mortalit

64 TIA1 is reported to be downregulated in obese patients, although it is not known if the effect i

65 d sleeve gastrectomy is feasible in morbidly obese patients and adds little additional operative time

66 We demonstrated that MGCs occurred in obese patients and after 24 weeks of a high-fat diet in

67 est level of risk reduction was observed for obese patients and for long-segment Barrett's esophagus.

68 avenues to ameliorate glucose homeostasis in obese patients and improve the effectiveness of metformi

69 on was almost 2 times higher among women and obese patients and more than 1.5 times higher among pati

70 cifically decreased in the adipose tissue of obese patients and murine models of genetic and nutritio

71 xtensiveness of conduction disorders between obese patients and nonobese patients measured at a high-

72 elopment of whole-body insulin resistance in obese patients and obese animal models.

73 ify factors associated with MetS in morbidly obese patients and predictors of its remission 12 months

74 r disease (NAFLD) is a frequent condition in obese patients and regularly progresses to non-alcoholic

75 c fatty-liver disease (NAFLD) is frequent in obese patients and represents a major risk factor for th

76 on the safety of pancreas transplantation in obese patients and suggest that they may be directed to

77 lysed differences in gene expression between obese patients and those at a normal weight in the COMPA

78 umour and peritumoral adipose tissue between obese patients and those at a normal weight.

79 To identify high-risk subgroups of obese patients and to examine the joint association of m

80 te to the pathogenesis of asthma severity in obese patients and warrant further investigation.

81 s SPECT in the overall population, in women, obese patients, and patients undergoing pharmacological

82 r for CAD detection and assessment of women, obese patients, and patients undergoing pharmacological

83 Obese patients are also at higher risk for venous thromb

84 Obese patients are more likely to be hospitalized with C

85 Obese patients are more vulnerable to development of atr

86 ngs of nutritional support in critically ill obese patients are needed.

87 a patients but also in a small subset of non-obese patients, are associated with more severe asthma.

88 feriority trial enrolling 8910 overweight or obese patients at increased cardiovascular risk from Jun

89 Among overweight or obese patients at increased cardiovascular risk, based o

90 uite effective, but is reserved for the most obese patients because of the associated intraoperative/

91 were measured simultaneously in 26 severely obese patients before and 1 year after RYGB, while patie

92 tes with elements of fat balance in severely obese patients before and after RYGB.

93 Steatorrhea and hyperoxaluria were common in obese patients before bypass, but hyperoxaluria was not

94 Overweight/obese patients (BMI > 25) did not show a significant dif

95 Overweight or obese patients (BMI >25 kg/m(2)) had a higher rate of ca

96 ociated with a lower mortality risk, whereas obese patients (BMI >30 kg/m(2)) had a mortality risk si

97 A logistic regression model showed that non-obese patients (BMI < 30 kg/m(2)) were at significantly

98 Obese patients(BMI 30-40) seeking VHR were randomized to

99 AF type before and after BS in 220 morbidly obese patients (body mass index, >=40 kg/m(2)).

100 In obese patients (body mass index, 48 +/- 11 kg/m), 21.7 +

101 We matched 51 morbidly obese patients [body mass index >=40 kg/m(2)] who had un

102 nd care needs of the critically ill morbidly obese patient but also navigate, both personally and pro

103 riodontal disease and OSAS risk in Class III obese patients, but OSAS risk was associated with both N

104 induces significant weight loss for severely obese patients, but there is limited evidence of the dur

105 AOBP decreased by 10.2 mm Hg ( P<0.0001) in obese patients, by 10.5 mm Hg ( P<0.0001) in blacks, and

106 Serum from obese patients caused organoids from L2-IL1B/IL8 mice to

107 tomic profiles of livers starting from a 910-obese-patient cohort, which was further stratified based

108 more prominent in the proximal tubules of 15 obese patients compared with 16 non-obese patients.

109 e data demonstrating a different response in obese patients compared with normal-weight patients duri

110 ptomic differences in the primary tumours of obese patients compared with those of a normal weight.

111 The gingival tissue miRNA profile of obese patients, compared to that of normal weight patien

112 Obese patients demonstrate greater adverse LV remodeling

113 Approximately 20-30% of obese patients do not achieve successful weight outcomes

114 , there is some evidence that full dosing in obese patients does not result in increased toxicity.

115 sing therapeutic target for the treatment of obese patients.Elevated plasma LPS levels have been asso

116 Morbidly obese patients exhibit impaired secretion of gut hormone

117 Obese patients exhibited higher expression levels of IL-

118 Five nonobese and two obese patients experienced potentially toxic piperacilli

119 Five severely obese patients (four women, one man) who were 31-49 year

120 iences of caring for critically ill morbidly obese patients from the perspectives of intensive care s

121 The control group consisted of 80 diabetic obese patients from the same period with similar body ma

122 mplications with VH repair (VHR) increase in obese patients (grade A), current smokers (grade A), and

123 ainly expressed DAPK2 and that DAPK2 mRNA in obese patients gradually recovered after bariatric surge

124 0.001), and after adjusting for confounders, obese patients had a significantly higher rate of tooth

125 similar among categories, but overweight and obese patients had longer hospital lengths of stay than

126 no significant differences in infarct size, obese patients had significantly more impaired LV global

127 total undigested adipose tissue (ATs), from obese patients has decreased LAL expression compared wit

128 In addition, obese patients have a higher incidence of early de-novo

129 Most obese patients have high endogenous levels of leptin, in

130 Compared with nonobese patients, obese patients have higher incidences of conduction diso

131 Obese patients have impaired vasodilator reactivity and

132 In conclusion, obese patients have increased risk for DGF.

133 Prior studies have found that obese patients have paradoxically lower in-hospital mort

134 0.80-1.09; OR: 0.95, 95% CI: 0.81-1.12) and obese patients (HR: 1.07, 95% CI: 0.78-1.48; OR: 0.96, 9

135 have had minimal representation of morbidly obese patients (ie, body-mass index [BMI] >=40 kg/m(2)),

136 For most morbidly obese patients, in addition to causing significant weigh

137 alyses, hypertension rates were higher among obese patients (incidence rate ratio [IRR] 1.70, 95% con

138 e, adipocyte-conditioned media obtained from obese patients increased IL32 gene expression in human m

139 positive end-expiratory pressure in morbidly obese patients is not well defined.

140 on, the survival of organs transplanted into obese patients is reduced compared with allografts in le

141 In obese patients, MAIT cells were more abundant in adipose

142 Morbidly obese patients may be at increased risk of delayed graft

143 is not linear, where overweight and class I obese patients may have an improvement in outcome.

144 Three groups were studied: morbidly obese patients (n = 16), morbidly obese patients who had

145 Compared to obese patients, nonobese patients had lower NAFLD activi

146 Bariatric surgery in obese patients not only improved their metabolic paramet

147 Twenty-seven obese patients (Ob) with T2D, 15 Ln-T2D, and 12 normal-w

148 atio = 0.59; 95% CI, 0.39-0.88) and severely obese patients (odds ratio = 0.46; 95% CI, 0.26-0.80) ha

149 Highest VTE risk was seen in obese patients [odds ratio (OR) = 1.41], those older tha

150 erior to ARFI for diagnosing any fibrosis in obese patients (P < 0.001) but not in nonobese patients

151 ients (P=0.020), and 41% higher for morbidly obese patients (P=0.015).

152 verweight patients (P=0.077), 28% higher for obese patients (P=0.020), and 41% higher for morbidly ob

153 Relative to obese patients, patients with a BMI of 18.5 kg/m(2) had

154 Results In this obese patient population (mean body mass index = 40.3 kg

155 Conclusion In this obese patient population, both MR elastography and VCTE

156 Critically ill morbidly obese patients pose considerable healthcare delivery and

157 ed for specific protocols to manage morbidly obese patients presenting to the ED with chest pain and

158 Severely obese patients, prior to bypass, ingest excess dietary f

159 Sixty-six morbidly obese patients randomized to SG or RYGB were included in

160 Among obese patients receiving care in the VA health system, t

161 d peritumoral adipose tissue inflammation in obese patients relative to those at a normal weight, esp

162 alcoholic fatty liver disease (NAFLD) in non-obese patients remains a clinical condition with unclear

163 Optimal chemotherapy dosing in obese patients remains uncertain, with variation in prac

164 ne expression analysis of liver samples from obese patients revealed a negative correlation between C

165 There is no difference in 2-year outcomes of obese patients seeking VHR who undergo prehabilitation v

166 erative prehabilitation improves outcomes of obese patients seeking VHR.

167 Morbidly obese patients selected for LRYGB were included in a pro

168 in conditioned media (CM) collected from the obese-patient, sera-exposed macrophages, an effect neutr

169 Morbidly obese patients should be considered for BS before atrial

170 Morbidly obese patients should be considered potential candidates

171 Preliminary data in a small cohort of obese patients show a similar association.

172 Tumours of obese patients showed higher angiogenic scores on gene-s

173 We found that overall survival was longer in obese patients than in those with normal weight in the T

174 In obese patients the risk of an ED visit or hospitalizatio

175 Among obese patients, the forced expiratory volume in 1 s (FEV

176 In obese patients, the hepatic CIDEC2 (human homologue of m

177 In obese patients, the overall incidence of CD (3.1% versus

178 In obese patients, the total number of enteroendocrine cell

179 odontal treatment was better among lean than obese patients; the remaining three studies did not repo

180 We assessed overall survival in obese patients (those with a body-mass index [BMI] >=30

181 olic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61)

182 opportunity to prevent colorectal cancer in obese patients through hormone replacement with the FDA-

183 k may be biased by preferential admission of obese patients to ICUs, and little is known about other

184 ing atrial fibrillation ablation in morbidly obese patients to those of nonobese patients.

185 cians could consider referring overweight or obese patients to Weight Watchers or Jenny Craig.

186 There is no guidance on dose for obese patients treated with biologic agents.

187 for severe obesity, less than 1% of severely obese patients undergo it.

188 Serum Ang-2 levels were determined in 104 obese patients undergoing bariatric surgery and concomit

189 es; and SAT, VAT, and liver tissues from 113 obese patients undergoing bariatric surgery at academic

190 s of adipocyte tissue macrophages (ATMs), in obese patients undergoing bariatric surgery.

191 aradox, morbidity and mortality are lower in obese patients undergoing cardiac surgery, although the

192 Prehabilitation may not be warranted in obese patients undergoing elective VHR.

193 Among obese patients undergoing surgery under general anesthes

194 t maneuvers improves respiratory function in obese patients undergoing surgery, but the effect on cli

195 Thirty-two obese patients underwent one of three treatments: (1) VS

196 In obese patients, using RNA sequencing, Seahorse analysis,

197 A survival advantage for overweight and obese patients was observed in this large cohort of crit

198 Antrum area during fasting in morbidly obese patients was statistically significant larger than

199 We carried out a cross-sectional study of obese patients, well characterized with respect to the s

200 om 16 mechanically ventilated critically ill obese patients were analyzed.

201 ns between intensive care staff and morbidly obese patients were challenging due to the social stigma

202 We also found that less obese patients were less likely to have higher and susta

203 Despite similar preoperative stage, obese patients were less likely to receive neoadjuvant t

204 osing of 16 g/2 g/24 hr continuous infusion, obese patients were more likely than nonobese patients t

205 Compared with normal/underweight patients, obese patients were younger and more likely to have diab

206 weight, 548 (10.7%) overweight and 67 (1.3%) obese patients, were included in this cohort.

207 Atelectasis develops in critically ill obese patients when undergoing mechanical ventilation du

208 1 was increased upon weight loss in morbidly obese patients, while Sparc expression was reduced.

209 We conclude that PI3Kgamma inhibition in obese patients who are predisposed to beta-cell failure

210 ibrillation ablation in addition to morbidly obese patients who did not undergo BS.

211 : morbidly obese patients (n = 16), morbidly obese patients who had had sleeve gastrectomy (n = 8), a

212 egistries of Nordic countries, we found that obese patients who have bariatric surgery have longer su

213 duction in the rate of HF exacerbation among obese patients who underwent nonbariatric surgery (i.e.,

214 ared arrhythmia recurrence rates in morbidly obese patients who underwent prior bariatric surgery (BS

215 We reviewed management issues in the obese patient with cancer, focusing on how obesity influ

216 endations for the surgical management of the obese patient with cancer.

217 from VA databases in overweight patients and obese patients with a weight-related disorder who had un

218 PATIENTS/Critically ill obese patients with acute respiratory failure and anesth

219 ardiorespiratory fitness on the prognosis of obese patients with AF.

220 A cohort of obese patients with and without type 2 diabetes mellitus

221 increased in the submucosa in a subgroup of obese patients with asthma (OAs).

222 a self-controlled case series study of 2261 obese patients with asthma aged 18 to 54 years who under

223 bronchial challenge and exercise testing in obese patients with asthma and misdiagnosed asthma compa

224 Fifty-five obese patients with asthma were randomly assigned to eit

225 Clinical control is difficult to achieve in obese patients with asthma.

226 an and rivaroxaban, and warfarin in morbidly obese patients with atrial fibrillation and venous throm

227 ough May 2013, one hundred and nine morbidly obese patients with biopsy-proven NASH underwent bariatr

228 erformed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the N

229 geted therapies may improve therapeutics for obese patients with breast cancer and identify patient p

230 ve the diagnosis, treatment, and outcomes of obese patients with breast cancer.

231 e conducted a case-controlled study with 106 obese patients with cirrhosis (cases) and 317 age, sex,

232 Further, obese patients with cirrhosis alone and in combination w

233 reduced BW and portal pressure in overweight/obese patients with cirrhosis and portal hypertension.

234 S) changes (diet and exercise) in overweight/obese patients with cirrhosis, and if weight loss reduce

235 ighly induced in the kidney of overweight or obese patients with CKD and ob/ob BTBR mice.

236 ribute to the apparent survival advantage in obese patients with clear cell RCC compared with patient

237 rmal weight patients (P=0.073), and morbidly obese patients with computerized tomographic scanning st

238 Importantly, obese patients with diabetes have a higher risk of infec

239 For most severely obese patients with diabetes, bariatric surgery seems to

240 nt for controlling hyperglycemia in severely obese patients with diabetes.

241 D management, particularly in overweight and obese patients with difficult glycemic control; and futu

242 These data suggest that morbidly obese patients with end-stage renal disease who undergo

243 However, obese patients with ESRD have limited access to kidney t

244 ered the weight loss procedure of choice for obese patients with gastroesophageal reflux disease (GER

245 ormed a self-controlled case series study of obese patients with HF who underwent bariatric surgery,

246 iring ED evaluation or hospitalization among obese patients with HF.

247 e effects of substantial weight reduction in obese patients with HF.

248 se with nonobese HFpEF and control subjects, obese patients with HFpEF displayed worse exercise capac

249 hronic inflammation, we investigated whether obese patients with hip OA exhibited differential pro-in

250 collected from normal-weight or over-weight/obese patients with hip OA.

251 Furthermore, obese patients with ILD had an elevated risk of death (H

252 rgy diet (LED) reduces weight effectively in obese patients with knee osteoarthritis, but the role of

253 Obese patients with leptin resistance show a variable re

254 ng the pathogenic mechanism in the subset of obese patients with low endogenous leptin levels.

255 may be a safe and effective intervention for obese patients with LVSD.

256 We studied 24 obese patients with MC4R deficiency, and 80 healthy cont

257 HR) and 95% CIs were 1.45 (1.12 to 1.82) for obese patients with MetSyn (n = 480); 1.09 (0.83 to 1.44

258 14, at a private MS referral center among 50 obese patients with MS who also developed MetS.

259 on, THEM2 levels were increased in livers of obese patients with NAFLD characterized by simple steato

260 therapeutic option for appropriate morbidly obese patients with NASH who do not respond to lifestyle

261 ry was both effective and cost-effective for obese patients with NASH, regardless of fibrosis stage;

262 erm effects of bariatric surgery in morbidly obese patients with NASH.

263 12, 2015, and Aug 4, 2016, 184 overweight or obese patients with non-alcoholic steatohepatitis were s

264 uman mINDY may have therapeutic potential in obese patients with nonalcoholic fatty liver disease.

265 MI 61 randomly assigned 12 000 overweight or obese patients with or at high risk for atherosclerotic

266 am improves gut barrier function and whether obese patients with or without liver steatosis differ in

267 Moreover, in non-obese patients with OSA, TGF-beta1 levels correlate with

268 R was confirmed by qRT-PCR as being lower in obese patients with periodontitis versus normal weight p

269 In severely obese patients with previous MI, metabolic surgery is as

270 We further show that obese patients with prostate cancer have increased epith

271 27 mmol/L to exclude the diagnosis of OHS in obese patients with sleep-disordered breathing when susp

272 Intestinal permeability is increased in obese patients with steatosis compared with obese patien

273 Hence, obese patients with stroke should continue to aim for no

274 biopsy specimens obtained from 13 overweight/obese patients with T2D and 14 weight-matched male contr

275 peptide (GIP) in the splanchnic region in 10 obese patients with T2D before and after bariatric surge

276 Obese patients with T2D show a greater propensity for ec

277 ith similar weight loss after SG and RYGB in obese patients with T2DM.

278 ted an obesity paradox, where overweight and obese patients with these disorders have a better progno

279 dical treatment for the long-term control of obese patients with type 2 diabetes and should be consid

280 Bariatric surgery is a treatment option for obese patients with type 2 diabetes mellitus (T2DM).

281 Of the 173 obese patients with type 2 diabetes mellitus undergoing

282 hanges of glucostatic parameters in morbidly obese patients with type 2 diabetes mellitus undergoing

283 A total of 27 obese patients with type 2 diabetes mellitus were random

284 e long-term outcomes of 2 groups of morbidly obese patients with type 2 diabetes mellitus-1 managed b

285 Using experiments in mice and overweight/obese patients with type 2 diabetes, we elucidated the s

286 ovascular and macrovascular complications in obese patients with type 2 diabetes.

287 markers of metabolism and liver fibrosis in obese patients with type 2 diabetes.

288 Among obese patients with uncontrolled type 2 diabetes, 3 year

289 ty-associated HCC, we measured plasma TnC in obese patients with various levels of liver injury.

290 tively screen for diabetes in overweight and obese patients with vascular disease, and pay increased

291 We hypothesize that prehabilitation in obese patients with VHR results in more hernia- and comp

292 Our results showed that surgery and ILI in obese patients (with F0-F3) increased QALYs by 0.678-2.1

293 Ongoing alcohol drinkers and morbidly obese patients, with minimal hepatic injury and steatosi

294 ody mass index-, and type of surgery-matched obese patients without cirrhosis (controls) who underwen

295 Morbidly obese patients without computerized tomographic scanning

296 Twelve obese patients without diabetes (8 women, mean age 43.1

297 etSyn (n = 417), and 1.00 (0.80 to 1.26) for obese patients without MetSyn (n = 324).

298 with 102 nonobese patients and 102 morbidly obese patients without prior BS on the basis of age, sex

299 ded and matched by propensity score to 3,882 obese patients without surgery.

300 obese patients with steatosis compared with obese patients without.